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AbstrAct
Introduction HIV remains underdiagnosed. Guidelines 
recommend routine HIV testing in primary care, but evidence 
on implementing testing is lacking. In a previous study, 
the Rapid HIV Assessment 2 (RHIVA2) cluster randomised 
controlled trial, we showed that providing training 
and rapid point-of-care HIV testing at general practice 
registration (RHIVA2 intervention) in Hackney led to cost-
effective, increased and earlier diagnosis of HIV. However, 
interventions effective in a trial context may be less so when 
implemented in routine practice. We describe the protocol 
for an MRC phase IV implementation programme, evaluating 
the impact of rolling out the RHIVA2 intervention in a post-
trial setting. We will use a longitudinal study to examine 
if the post-trial implementation in Hackney practices is 
effective and cost-effective, and a cross-sectional study to 
compare Hackney with two adjacent boroughs providing 
usual primary care (Newham) and an enhanced service 
promoting HIV testing in primary care (Tower Hamlets).
Methods and analysis Service evaluation using 
interrupted time series and cost-effectiveness analyses. 
We will include all general practices in three contiguous 
high HIV prevalence East London boroughs. All adults 
aged 16 and above registered with the practices will be 
included. The interventions to be examined are: a post-trial 
RHIVA2 implementation programme (including practice-
based education and training, external quality assurance, 
incentive payments for rapid HIV testing and incorporation 
of rapid HIV testing in the sexual health Local Enhanced 
Service) in Hackney; the general practice sexual health 
Network Improved Service in Tower Hamlets and usual 
care in Newham. Coprimary outcomes are rates of HIV 
testing and new HIV diagnoses.
Ethics and dissemination The chair of the Camden and 
Islington NHS Research Ethics Committee, London, has 
endorsed this programme as an evaluation of routine care. 
Study results will be published in peer-reviewed journals 
and reported to commissioners.
IntroductIon 
HIV prevalence is increasing, with over 
100 000 people now estimated to be living 
with HIV in the UK.1 From 1999 to 2013, the 
numbers of patients accessing specialist care 
increased fourfold.2 3 Successfully treated, 
HIV now has characteristics of a long-
term condition, with patients taking life-
long treatment and increasingly exhibiting 
age-related comorbidities, such as cardio-
vascular disease, osteoporosis and mental 
illness. The cost of HIV care for the National 
Health Service (NHS) (without considering 
the cost of treating comorbidities) in 2013 
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Protocol
strengths and limitations of this study
 ► The study will use existing trial data preceding the 
implementation programme in addition to post-trial 
data, collected using similar methods to those used 
in the trial.
 ► Fully anonymised general practice data from all 
participating boroughs will be remotely extracted 
using a single general practice computer system 
(Egton Medical Information Systems, EMIS).
 ► A large dataset with at least 12 time points before 
and at least 29 time points after the intervention 
implementation will provide precise estimation of 
the effects of intervention using interrupted time 
series analysis.
 ► Differences in HIV testing protocols, data quality 
and extraction between Hackney, and Tower 
Hamlets and Newham; and previous interventions 
such as rapid HIV testing pilots in a small number 
of Newham practices, may affect comparability 
between boroughs. Also, cross-contamination of 
Rapid HIV Assessment 2 (RHIVA2) control practices 
from intervention practices, or between boroughs, 
may have occurred.
 ► Finally, the post-trial implementation programme 
of the RHIVA2 intervention differed slightly from the 
research intervention to account for the complexities 
of delivering services in routine healthcare settings.
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was estimated to be £750 million (£1billion with social 
care included).4 
Late diagnosis of HIV increases morbidity and mortality, 
and is associated with unwitting onward transmission. To 
reduce the pool of undiagnosed infection in the population, 
the British HIV Association (BHIVA) and National Institute 
for Health and Care Excellence (NICE) recommended 
expansion of routine HIV testing from sexual health and 
antenatal clinics to non-traditional settings including 
general practices located in high HIV prevalence areas (two 
or more people diagnosed with HIV/1000 adult popula-
tion).5–8 In the Framework for Sexual Health Improvement 
in England (2013), the UK Department of Health addi-
tionally set out recommendations for the commissioning of 
HIV testing in high prevalence areas across all healthcare 
settings, including general practice.9 However, the decision 
to implement these recommendations lies with the 74 local 
authorities in England and the respective clinical commis-
sioning groups (CCGs). Although National Policy for HIV 
screening in antenatal settings has proven highly effective, 
guidance for screening in general practice is lacking. Indeed, 
it was hoped that recommending routine HIV testing would 
suffice to enhance awareness of HIV among general prac-
titioners (GPs) and become standard in this setting.10 Pilot 
studies have demonstrated feasibility and acceptability of 
routine HIV testing among patients and healthcare profes-
sionals.11 12 Despite this, a recent systematic review identified 
low uptake of routine HIV testing in non-traditional UK 
settings including general practice following the BHIVA 
2008 guidelines.13
In a large-scale pragmatic cluster randomised controlled 
trial (Rapid HIV Assessment 2 (RHIVA2)) in the London 
borough of Hackney, we showed that rapid HIV testing 
offered at general practice registration was effective and 
safe, and delivered increased and earlier HIV diagnosis.14 
Furthermore, a recent health economics analysis of the 
RHIVA2 trial demonstrated that HIV screening in primary 
care in high HIV prevalence areas is cost-effective.15 
Following completion of this trial, we implemented HIV 
testing into routine care across all Hackney practices using 
a theory-based programme16–18 comprising an adaptation of 
the RHIVA2 intervention, including a practice-based educa-
tion programme, a borough-wide audit of HIV care, and the 
introduction of payments for routine HIV testing as part of 
an updated general practice sexual health Local Enhanced 
Service (LES).19
We will evaluate both the RHIVA2 trial and post-trial 
implementation programme through an MRC phase IV 
implementation study.20 The study will also compare the 
impact of RHIVA2 implementation in Hackney practices 
with two neighbouring boroughs; Tower Hamlets that 
offers a general practice sexual health Network Improved 
Service (NIS) promoting routine HIV testing; and 
Newham offering usual primary care without incentivised 
HIV testing.
Figure 1 summarises the timelines of HIV-related inter-
ventions in these three boroughs.
The study will therefore address the following questions:
 ► How effective and cost-effective is the RHIVA2 inter-
vention when implemented as a clinical service 
outside a research context?
 ► How do effectiveness and cost-effectiveness of the 
RHIVA2 trial and implementation programme 
compare with a borough-wide sexual health NIS 
promoting routine HIV testing in Tower Hamlets?
 ► How do both the RHIVA2 trial and post-trial imple-
mentation programme and the Tower Hamlets sexual 
health NIS compare with Newham that offers usual 
HIV primary care only?
MEthods And AnAlysIs
setting
The study will be set in the three East London boroughs 
of Hackney, Tower Hamlets and Newham. The estimated 
diagnosed HIV prevalence for these boroughs is 8.1, 6.5 
and 6.7 per 1000 adult population, respectively.21 We 
will include all adults aged 16 and above registered with 
general practices in the three boroughs.
design
Service evaluation comprising a pragmatic cohort using 
an interrupted time series (ITS) analysis and cost-effec-
tiveness analysis. The evaluation will examine the longi-
tudinal impact of interventions in Hackney and the 
comparative cross-sectional impact of interventions in 
Hackney, Tower Hamlets and Newham. HIV testing and 
diagnosis data from 1 April 2009 to 30 June 2015 is being 
collected.
Interventions
Hackney
The RHIVA2 intervention was first introduced in April 
2010 in 20 general practices randomised to the interven-
tion arm of the RHIVA2 trial (table 1). This theory-based 
intervention16–18 is described in detail in Leber et al14 and 
consisted of a practice-based educational training session 
for the primary care team to promote rapid HIV testing 
at registration, a follow-up meeting with a nominated 
practice lead nurse, integration of rapid HIV testing with 
the general practice computer template, and an incentive 
payment of £10 per rapid HIV test performed. Testing 
competence was monitored by an external quality assess-
ment. This intervention was offered in addition to an 
existing national antenatal HIV screening service offered 
at the practices, and a sexual health LES promoting sexual 
health screening including HIV case detection (incentive 
payments of £265 per newly diagnosed patient) intro-
duced in 2006/2007.19
The RHIVA2 post-trial implementation programme ran 
from September 2012 to June 2015 and comprised the 
following three components16–18:
1. Additional post-trial HIV testing training (September 
2012 to February 2013). This was offered to all 
Hackney practices at the completion of the RHIVA2 
trial and comprised a modification of the RHIVA2 tri-
al intervention whereby practices were encouraged to 
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Figure 1 Sexual health service provision in East London general practice. In Hackney (blue), the Rapid HIV Assessment 
(RHIVA) research programme promoting rapid point-of-care HIV testing was developed in addition to a sexual health local 
enhanced service (LES) and included: a pilot study (RHIVA1), a cluster randomised controlled trial across 20 intervention 
practices (RHIVA2) and implementation of the RHIVA2 intervention across all Hackney practices. In April 2013, the RHIVA2 
intervention was integrated with the sexual health LES. In Tower Hamlets (red), a sexual health network improved service (NIS) 
replaced the previous LES in April 2011. Newham (green) does not provide a service promoting HIV testing (usual care). BHIVA, 
British HIV Association; DoH, Department of Health; NICE, National Institute for Health and Care Excellence.
offer both routine serology and rapid HIV testing in 
any clinical setting (rather than just rapid testing at 
practice registration).
2. Updated sexual health LES. From April 2013, the ex-
isting LES was replaced with HIV testing payments to 
practices of between £7 and £10 for every rapid or se-
rology HIV test carried out in any clinical setting, in 
addition to a payment of £258 for any new diagnosis.
3. General practice-based HIV care audit (October 2012 
to March 2013) of missed diagnoses of HIV and safe-
ty of coprescribing with antiretroviral medication in 
Hackney general practices.22
Tower Hamlets
In April 2011, Tower Hamlets implemented sexual health 
NIS incentive payments promoting cooperation between 
practices in eight practice networks, comprising four to 
five practices each.
The NIS incentivised sexually transmitted infections 
(STIs) testing with separate payments for serology (£10 
per HIV test combined with or without hepatitis B and 
syphilis testing) and swabs/urine (£15 for gonorrhea and 
chlamydia testing).
Practices were encouraged to offer HIV and STI testing 
as part of the new patient check as well as in sexual health 
and contraception consultations and opportunistically in 
general consultations.
In contrast to Hackney, where practices received the 
implementation individually over a 6-month period, the 
Tower Hamlets sexual health NIS went live through acti-
vation of the computerised sexual health template on 
the same day for all practices (April 2011). A primary 
care facilitator in sexual health (JH since September 
2012) has additionally provided regular support, 
training and performance feedback to the practice 
networks.
Newham
Usual care—no specific borough-wide initiatives were 
promoted relating to HIV testing in primary care.
The RHIVA2 intervention is based on published clini-
cian behaviour change programmes,16–18 and the Tower 
Hamlets NIS follows Royal College of General Practi-
tioners guidance on establishing general practice feder-
ations.23 We will report our study in accordance with the 
STARI reporting guidelines for implementation studies.24
outcome measures
All data gathered will comprise routine clinical data. No 
identifiable data will be held by the research team.
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Table 1 Schedule for enrolment, interventions and assessment of the study
Timepoint
Study period
Control period
Practice 
allocation Post-allocation Close-out
−41 
months
−24 
months
−12 
months 0 months
+1 
months
+2 
months
≥12 
months
+29 
months
+34 
months
+51 
months
RHIVA2 trial: X
  Allocation X
  Intervention X
  Enrollment X X X
RHIVA2 post-trial 
implementation:
X
  Allocation X
  Intervention X
  Enrollment X X X X
Tower Hamlets: X
  Allocation X
  Intervention X
  Enrollment X X X X X X X
Assessments:
  HIV testing X X X X X X X X X X
  HIV diagnosis X X X X X X X X X X
RHIVA2, Rapid HIV Assessment 2.
Coprimary outcome measures
 ► Rates of HIV testing (combined rapid and serology 
testing; number of patients tested/1000 population/
year)
 ► Rates of new HIV diagnosis (number of newly diag-
nosed patients/10 000/year)
Secondary outcome measures
Secondary outcome measures will include data on type 
of HIV test (serology; rapid), location of diagnosis, stage 
of disease and linkage to secondary care and retention in 
secondary care:
 ► Number/rate of patients who received a rapid HIV 
test.
 ► Number/rate of patients who received a serology HIV 
test.
 ► Number/rate of patients newly diagnosed in general 
practice.
 ► Mean and median CD4 count of patients newly diag-
nosed in primary care.
 ► Proportion of patients with a CD4 count <350 cells/
μL of blood.
 ► Proportion of patients with a CD4 count <200 cells/
μL of blood.
 ► Proportion of patients newly diagnosed with HIV in 
primary care who attend an HIV specialist depart-
ment within 1 week of diagnosis.
 ► Proportion of patients newly diagnosed with HIV in 
primary care who attend an HIV specialist department 
within 2 weeks of diagnosis (BHIVA Standards of Care 
for people living with HIV (PLHIV), Standard 2, 
2013).25
 ► Proportion of patients newly diagnosed with HIV in 
primary care who attend an HIV specialist department 
within 4 weeks of diagnosis (NHS England Standard).
 ► Proportion of patients newly diagnosed with HIV in 
primary care who attend a HIV specialist department 
within 3 months of diagnosis (Optimising testing and 
linkage to care for HIV across Europe, OptTEST, 
2013).
 ► Number of patients previously known to have HIV, 
who attend an HIV specialist clinic between 12 and 
24 months following new diagnosis in primary care 
(BHIVA Standards of Care for PLHIV, Standard 2, 
2013).
data sources
We will gather data from April 2009 to June 2015 using 
the following sources.
Organisational data
For Hackney practices, we hold detailed records of 
RHIVA2 trial educational training sessions, post-trial 
education sessions and participation in the borough-wide 
audit of HIV care. For Tower Hamlets, we hold data on 
timing of the introduction of the NIS. For all boroughs, we 
will seek to obtain any other relevant activities promoting 
HIV testing in the practices.
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Clinical data
HIV diagnosis data
Borough-specific master case report forms (CRF) 
containing lists of patients with a positive confirmatory 
HIV test result will be generated by the lead HIV clini-
cian from the clinical HIV services in each borough. 
This master CRF will be shared with the study team in 
an anonymised format as per the RHIVA2 protocol. At 
Homerton Hospital, Hackney data on newly diagnosed 
patients have been collected prospectively as outlined 
in RHIVA2 (continuous data available from 2009). For 
Tower Hamlets and Newham, new diagnosis data will be 
collected retrospectively for the same period. Clinical 
leads will liaise with Public Health England to categorise 
patients with a positive confirmatory HIV test into newly 
diagnosed patients and people already known to be HIV 
positive, and obtain data on patients who had defaulted 
from care between 12 and 24 months following diagnosis.
HIV testing data
In collaboration with the Clinical Effectiveness Group in 
the Centre for Primary Care and Public Health (QMUL), 
we will collect anonymised data on HIV testing in primary 
care, as per RHIVA2 protocol, using remote searches of 
borough-specific READ codes used for rapid and serology 
HIV testing.
sample size and analysis
Sample size
Sample size calculations for the ITS analysis are based on 
the number of time points available to perform the anal-
ysis. Generally, a minimum of 10–12 time points before 
and after an intervention are required to determine statis-
tical significance of an intervention.26 27 Twelve monthly 
time points are available before the RHIVA2 trial inter-
vention and a minimum of 13 time points for the period 
thereafter; and 41 monthly time points are available 
before the RHIVA2 implementation and a minimum of 
29 time points thereafter. For Tower Hamlets, 24 monthly 
time points are available before the introduction of the 
sexual health NIS and a minimum of 51 time points 
thereafter.
Longitudinal analysis of effectiveness of RHIVA2 implementation 
programme in Hackney
We will compare testing rates using an ITS regression 
approach with a mixed Poisson model (or negative bino-
mial model if there is overdispersion) to analyse the 
effect of interventions. Mixed Poisson regression will 
allow for the clustered nature of the data, that is, allowing 
each practice to have a different intercept (baseline HIV 
testing rate). We will also adjust for practice list size as an 
offset variable in the analysis. Using this approach, it will 
be possible to examine whether there is a change in level 
and/or a change in regression slope following the imple-
mentation of the intervention.
We will first examine the impact of the RHIVA2 inter-
vention on combined serology and rapid HIV testing rate 
in practices that received the RHIVA2 implementation 
(post-trial setting, comparing testing rates preinterven-
tion and postintervention). We will repeat this analysis 
including practices which did not receive the RHIVA2 
intervention during the trial or the further implemen-
tation phase, to act as a comparator. This will allow 
comparison of testing rates in practices postimplementa-
tion to their preimplementation rates, also adjusting for 
continuing trends in practices that did not receive the 
RHIVA2 implementation. We will also repeat the analysis 
using Newham practices (which received no interven-
tion) as a further comparator.
The date of intervention will be defined as the date of 
the first RHIVA2 training session. We will conduct similar 
analysis to the above, with the endpoint of HIV diagnosis, 
rather than testing.
To assess sustainability, we will model testing rates in 
practices that received the RHIVA2 intervention during 
the trial period, considering an interaction term between 
time postintervention and whether practices were 
retrained. This will allow an assessment to be made about 
whether retraining influences the slope postintervention, 
that is, the sustainability of the RHIVA2 intervention.
Cross-sectional analysis of effectiveness of the RHIVA2 
implementation programme in Hackney, a sexual health NIS in 
Tower Hamlets and usual care in Newham
We will examine the impact of the sexual health NIS on 
the serology testing rate in all Tower Hamlets practices 
(comparing testing rates preimplementation and post-
implementation). We will repeat this analysis but also 
including practices in Newham, which received no inter-
vention at any stage, to act as a comparator. The date of 
intervention will be defined as the date when the sexual 
health NIS system went live for all practices (April 2011). 
We will also compare the RHIVA2 implementation in 
Hackney with the introduction of the sexual health NIS 
in Tower Hamlets.
We will conduct similar analysis to the above, with the 
endpoint of HIV diagnosis, rather than testing.
cost-effectiveness analysis
Cost-effectiveness analyses for the longitudinal and 
cross-sectional analyses described above will build on a 
cost-effectiveness model developed for the RHIVA2 trial.15 
To assess value for money, we will identify the difference 
in costs and the difference in benefits of implementing 
the RHIVA2 intervention and we aim to distinguish 
between two different analyses. First, we will evaluate the 
cost-effectiveness of the RHIVA2 implementation using 
the same ‘comparator’ defined in the longitudinal anal-
ysis, that is, practices which did not receive the RHIVA2 
intervention at any stage will be considered the ‘absence 
of the intervention’.
Second, we will build a cost-effectiveness compar-
ison between different forms of HIV screening in East 
London, formally comparing the RHIVA2 implemen-
tation (conducted in Hackney) with the sexual health 
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NIS (Tower Hamlets) and usual care (Newham). Once 
again, all three different approaches will be compared 
with practices, which did not receive the RHIVA2 inter-
vention at any stage, as these are considered the ‘absence 
of the intervention’. Given that the same control group of 
practices in Hackney will serve as reference, this second 
analysis will formally compare the different approaches 
from different boroughs, considering no intervention in 
Hackney as a reference.
Three main cost categories will be explored: (1) the 
extra start-up cost of RHIVA2 implementation (specifi-
cally the cost for RHIVA2 staff time, including follow-up 
activities; cost of training; cost of training materials and 
cost of incentives to practices); (2) the extra recurrent 
cost for performing rapid HIV testing and (3) additional 
costs associated with reactive rapid HIV test results.
Benefits of the RHIVA2 programme will include 
health outcomes for patients, specifically deaths averted, 
secondary HIV infections averted and quality-adjusted life 
years; these are a function of the uptake of screening and 
screening positivity, which will be quantified directly by 
the analyses.
This study is a service evaluation which does not require 
registration as a trial.
EthIcAl AspEcts
The programme described is an evaluation of routine care. 
Its status as such has been endorsed by the chair of the 
Camden and Islington NHS Research Ethics Committee 
London. The committee’s view is that the work does 
not require NHS ethics approval. The programme will 
be implemented in partnership with the local providers 
and commissioners and involve the analysis of existing 
routine data. This also applies to data on delayed diag-
nosis of HIV (CD4 count), and demographics reported 
in the RHIVA2 trial, which is routinely collected as part 
of a national audit (BHIVA National Audit 2010) and 
has been included in Public Health Outcomes Frame-
work (http://www. phoutcomes. info). We will inform the 
research ethics committee, the CCG and Public Health 
about any important changes to the protocol.
This service evaluation is to answer the question: what 
standard does this service achieve? It involves routine 
implementation of an intervention outside of the research 
context. The actual management options are those of 
the clinician and patient only. There is no random allo-
cation to intervention and control groups. No individual 
consent is required from newly diagnosed patients.
In addition to CD4 count and viral load, the following 
additional data will be obtained by the clinical leads of 
specialist departments in an anonymised fashion and 
stored in accordance with good clinical practice:
 ► Most likely mode of HIV acquisition
 ► Sexual orientation
 ► Soundex code
 ► Ethnicity
 ► Gender
 ► Age at diagnosis.
dIscussIon
The MRC Framework for complex interventions28 clearly 
describes the need for implementation studies that test 
the effectiveness of interventions found to be promising 
in phase III randomised controlled trials. Successful 
translation of such interventions into routine care 
cannot be assumed; trials take place in tightly controlled 
conditions that aim to limit bias, with selected (often 
motivated) participants, while implementation 
programmes (usually) aim much more broadly to 
include all potential participants.29 Trial interventions 
will often need to be augmented by a distinct implemen-
tation package. Their success will be affected by multiple 
factors including, but not limited to contextual factors 
such as, differences in setting, population, organisation 
of healthcare systems, competing initiatives and finan-
cial aspects (including availability of incentives). Evalu-
ations of implementation of trials into routine care are 
frequently not carried out, and if they are, are often 
poorly reported.30 Such evaluations are highly unlikely 
to involve randomised designs, and are more likely to be 
observational, including the use of service evaluations. 
Designs are often constrained by health systems and data 
availability, but need to be as robust as possible. New 
reporting guidelines have recently been published that 
highlight the need for evaluation of implementation and 
aim to improve their reporting, such that they can be 
more easily accessed in the literature and serve to guide 
others in designing the most effective implementation 
programmes.29
Recent NICE guidelines recommend expanded HIV 
testing in primary care,6–8 but little information is avail-
able about how to operationalise testing, especially in 
the context of current resource constraints in primary 
care. It is, therefore, vital that innovative and effective 
ways are found to implement testing. The strengths of 
the proposed work include the availability of existing 
trial data preceding the implementation programme, 
the capacity to collect data longitudinally using similar 
methods to those used in the trial, and the use by general 
practices across all three participating boroughs of a 
single GP computer system supplier Egton Medical Infor-
mation Systems, data from which can be remotely and 
electronically (with full anonymisation) searched and 
collated by the research team (http://www. blizard. qmul. 
ac. uk/ ceg- home. html), confirmation of HIV test results 
for all study practices at the same tertiary care laboratory 
(Barts Health NHS Trust) and external data validation by 
Public Health England. This approach provides a unique 
capability, allowing comparative data on three separate 
approaches to HIV testing and diagnosis to be accurately 
gathered and analysed.
Due to difference in data extraction between Hackney 
and Tower Hamlets and Newham, respectively, there may 
be a small chance of differential reporting bias between 
these boroughs. In contrast to the Department of Sexual 
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Health at Homerton University Hospital (Hackney), 
which is able to track any patient lost to follow up using a 
monthly list of HIV positives provided by the laboratory, 
no such fail-safe procedure exists in Tower Hamlets or 
Newham. However, in these latter boroughs all data for 
HIV positive test results are available on the general prac-
tice computer system via an electronic laboratory link, 
almost eliminating the chance of missing data. We are 
currently conducting an audit of outcomes from people 
newly diagnosed with HIV in Tower Hamlets and Newham 
general practices to extract this data for the study period 
specified.
We cannot exclude occurrence of any cluster or cross-
over effects, although we would expect for this to be 
minimal given that we detected a more than fourfold 
increase in HIV testing rates between the RHIVA2 trial 
intervention and control practices. In contrast to the 
network structure in Tower Hamlets, Hackney practices, 
which were randomly allocated to the trial arms, may have 
informally worked collaboratively through geographical 
proximity. Due to this potential clustering effect, infer-
ence of generalisability of RHIVA2 findings in other 
boroughs should, therefore, be treated with caution. 
Furthermore, an audit of new diagnosis and safe copre-
scribing was also conducted by our team across 31 of the 
44 Hackney practices during the implementation phase‚ 
potentially causing contamination of control practices. 
However, the number of both trial intervention (n=13) 
and control (n=15) practices was comparable, suggesting 
equal exposure to this audit across both arms.22 Although 
public health teams informally collaborate across North-
east London, crossover between boroughs is unlikely 
given that services are developed and budgeted sepa-
rately. Our analysis will adjust for any potential contam-
ination using various vertical and horizontal controls 
both within Hackney, as well as between boroughs using 
Newham, which has been devoid of any local service HIV 
promotional intervention, as control.
Moreover, the RHIVA2 trial and post-trial implemen-
tation will not be grouped as the same intervention. We 
will only use the post-trial implementation practices in 
the main analysis and only consider the trial intervention 
practices for the assessment of sustainability. Therefore, 
the sustainability analysis will have to be interpreted with 
caution with regards to the sustainability of the post-trial 
intervention, as the intervention in trial conditions might 
be different to that outside of trial conditions.
We may not be able to account for missing data such as 
from patients lost to follow-up after diagnosis in general 
practice, or from rapid testing pilots conducted in a small 
number of Newham practices during the study period.
Finally, the RHIVA2 trial intervention was adapted for 
the implementation phase (1) to expand promotion of 
routine offer of HIV testing from new registration checks 
to include sexual health and contraception appointments 
and (2) to enhance screening through additional use of 
venous blood sampling. This protocol adaptation was 
made to meet the needs of the local population through 
increasing access to testing, reflecting the complexities of 
translating a research intervention into clinical practice 
after completion of the research.
The results of the proposed analysis are likely to 
be of considerable interest to commissioners, partic-
ularly given that late diagnosis of HIV is a UK Public 
Health Outcomes Framework priority,31 and that 
cost-effectiveness of HIV testing is complex, and becoming 
cost-effective in trial-based models only after a period of 
time has elapsed to counter the additional significant 
costs of early treatment.
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